DNAprint Genomics (DNAG)

[dgplexus]

"frogdreaming,"

So, according to what you just said, you are 100% against the principle of how publicly traded R&D companies operate. They are publicly traded, so they can raise needed funding by selling shares. People buy those shares, when they think the prospects are good, and the shares are a good value. Obviously, averaging down is an important part of wise investing in R&D stocks. It's difficult to predict the moment when the R&D company becomes profitable, and the goal is to average down relatively close to the time that it does so, to maximize your potential returns. DNAG is no different. It's not DNAG's fault, that you have this philosophical issue with R&D stocks.

> Any stock that is dumping shares to pay the bills can have only one direction, the laws of supply and demand automatically dilute the value of each share as each new share is added to the OS. When a company has no other revenue source than the printing and dumping of shares, the pps has only one direction available to it. To 'average down' under such conditions is tantamount to setting your money on fire. LOL